1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
Pharmigene, Inc.

Pharmigene, Inc.

TTPEX:7595
7.70
TWD
+0.25
(+3.36%)
366.88MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.87
3.54
2.97
3
2.98
3.08
2.92
2.31
3.96
- -
Basic EPS, GAAP
-0.4
-0.61
-1.6
-0.33
-0.54
-0.98
-1.6
-1.64
-1.45
- -
Free Cash Flow per Basic Share
-1.44
-0.77
-1.13
-0.64
-0.87
-0.78
-16.39
-2.22
-1.51
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
4.12
3.82
3.01
9.42
8.79
7.82
8.8
6.92
5.52
5.16
Tangible Book Value per Share
3.77
3.5
2.84
9.28
8.43
7.49
8.52
6.65
5.3
4.96
Basic Weighted Avg Shares
19
22
22
34
43
43
45
50
50
50
Sales/Revenue/Turnover
55
78
65
101
129
134
133
117
200
- -
Operating Margin (%)
-14.9
-14.85
-47.98
-12.3
-18.69
-32.78
-44.55
-69.75
-28.31
- -
Depreciation Expense
2
5
10
12
15
20
23
24
26
- -
Net Income, GAAP
-8
-13
-35
-11
-23
-43
-73
-83
-73
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-13.92
-17.21
-53.78
-11.06
-18.12
-31.93
-54.74
-71.11
-36.52
- -
Working Capital
158
137
103
313
261
220
217
198
81
72
LT Debt
- -
- -
14
15
8
4
565
600
570
579
Total Equity
179
166
131
410
382
340
444
349
278
260
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-7.76
-23.67
-4.15
-5.92
-11.83
-18.54
-20.89
-23.27
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
38
85
58
LT Borrowings
578
569
576
LT Finance Leases
2
1
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
50
50
50
Market Capitalization
608
500
367

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
178
219
150
Cash, Cash Equivalents & STI
77
87
93
Accounts Receivable, Net
36
51
16
Inventories
50
44
34
Total Current Liabilities
72
138
78
Payables & Accruals
- -
- -
- -
ST Debt
38
85
58
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-5.74%
-20.23%
Free Cash Flow
- -
407.25%
-31.67%
Net Income, GAAP
- -
52.73%
-11.91%
Sales/Revenue/Turnover
- -
17.92%
71.53%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
117
2025
- -
- -
200
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.64
2025
- -
- -
-1.45
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Fu Hui Chan
Full Time Employees
42
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
No. 17, Lane 171, Section 2, Jiuzong Road Taipei TP Taiwan 114066
IPO Date
Dec 22, 2020
Website
pharmigene.com
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
Pharmigene, Inc. designs, develops, manufactures, and sells molecular diagnostic tests primarily in Taiwan and internationally. Its core product portfolio includes molecular diagnostics for adverse drug reactions, DNA extraction kits for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics tests, drug allergy tests, functional medicine test services, and distributes various genomics and genetics equipment and reagents. Additionally, Pharmigene offers contract development and manufacturing organization (CDMO) services and professional consultation, training programs, analysis software, and technical support solutions. Founded in 1994 and headquartered in Taipei, Taiwan, Pharmigene operates in the biotechnology and pharmaceuticals sector with a focus on precision medicine and personalized diagnostics. Recent major company developments include the acquisition of ISO 13485 and TFDA QMS certifications for its new manufacturing facility in New Taipei City, enabling enhanced medical device manufacturing capabilities and preparation for expanded contract manufacturing services. The company also announced strategic collaborations with technology partners to advance biomarker development and clinical service offerings related to cancer companion diagnostics and regenerative medicine. Pharmigene’s products and services cater to hospitals, laboratories, and biomedical research institutions primarily in Taiwan and other Asian markets. The company continues to expand its clinical and R&D focus through partnerships with leading medical institutions such as National Taiwan University Hospital to better align its product pipeline and diagnostic innovations with emerging clinical needs.